Overview
RANI market data
Price History
RANI price chart · 1M
- O
- 0.857400
- H
- 0.859900
- L
- 0.853600
- C
- 0.853600
- Vol
- 2,685.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.86
- Previous Close
- $0.84
- Day High
- $0.86
- Day Low
- $0.85
- 52 Week High
- $1.14
- 52 Week Low
- $0.61
- 7 Day Return
- -1.36%
- 30 Day Return
- +3.71%
- 90 Day Return
- -10.26%
- 1 Year Return
- -1.39%
- Daily Notional Volume
- $2.3K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.45 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.78 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -547.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.44 – $3.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $108.8M · P/B 4.97 · P/S 34.33.
Company News
HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price TargetBenzinga · Aug 21, 2026, 10:31 AM
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Aug 18, 2026, 12:45 PM
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6Benzinga · Aug 18, 2026, 11:53 AM
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K EstimateBenzinga · Aug 13, 2026, 8:32 PM
8-K filing — Rani Therapeutics Holdings, Inc. (RANI)SEC EDGAR · Aug 13, 2026, 8:11 PM
Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist ClassBenzinga · Jul 15, 2026, 12:04 PM
Rani Therapeutics Partners With PegBio To Mull Delivery Of Multiple Novel Candidates From PegBio's Obesity And Metabolic Disease Pipeline Through RaniPill PlatformBenzinga · Jul 9, 2026, 8:10 PM
Rani Therapeutics Appoints Nicholas Maestas As CFO; Succeeds Svai SanfordBenzinga · Jun 29, 2026, 12:10 PM